Vir Biotechnology Inc (VIR) Stock Price, Quote & News

Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metap...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 906 4324

Website: www.vir.bio

Address:

1800 Owens Street, Suite 900, San Francisco, United States

Dunnieboy1 Dec. 10 at 8:06 PM

$VIR are in London tomorrow for the Biotech industry’s annual award, were finalists in the ’business development team of the year’, we were nominated on the back of the Sanofi deal, we paid a total of $170M for three of their programs (plus milestones payments) two of which were already in phase 1 trials & a third trial about to begin, the 3rd trial has now started, we also took 50 scientists as part of the deal. Good luck Vir.

4 · Reply

VIR_Tical1 Dec. 9 at 9:18 PM

$VIR Validation of HDV Market Opportunity The $820M deal (for a Phase 3 asset) signals “very high interest” in HDV, highlighting its unmet need and revenue potential despite being a rare disease. Mirum’s $750M+ sales forecast underscores a non-zero-sum market where multiple therapies can coexist. Superior Clinical Profile Needham views VIR’s elebsiran/tobevibart combo as “better” than Bluejay’s brelovitug (monoclonal-only, less durable suppression) or GILD’s bulevirtide (subcutaneous daily dosing vs. VIR’s potential quarterly IV/subQ). VIR’s data shows deeper HBsAg/HDV reductions and functional cure potential.

0 · Reply

VIR_Tical1 Dec. 9 at 9:15 PM

$VIR - Here’s what Grok (xAI’s AI) said when I asked about the VIR/Bluejay/Mirum deal: Why This Benefits Vir Biotechnology (VIR) VIR is developing a combo regimen for HDV: elebsiran (an siRNA that suppresses HBsAg production) + tobevibart (a monoclonal antibody neutralizing HBsAg and virions). Their Phase 2 SOLSTICE study showed promising Week 48 data (HDV RNA suppression in ~80-90% of patients), with Phase 3 ECLIPSE trials ongoing and readout expected in 2026—positioning VIR as a potential first- or second-to-market player. Needham argues this profile outperforms Bluejay’s single-agent brelovitug and even Gilead’s (GILD) bulevirtide (recently approved but with injection burdens and reimbursement hurdles). Here’s a breakdown of the specific benefits:

0 · Reply

Dunnieboy1 Dec. 9 at 5:16 PM

$VIR are we building up to a ‘santa rally’, December historically is a strong month for the markets, with the 5 days leading up to xmas & the two days prior to new year being particularly strong.

0 · Reply

VIR_Tical1 Dec. 9 at 2:10 AM

$VIR From MSN: Needham reiterated a Buy rating and $14 price target on Vir Biotechnology (VIR), saying that Mirum’s (MIRM) announced takeover of Bluejay Therapeutics is a positive readthrough to Vir. The firm believes this given its view that Vir’s elebsiran/tobevibart profile is better than Bluejay and Gilead (GILD); the deal signals very high interest in the Hepatitis Delta Virus commercial opportunity, and; the deal size is quite favorable for a potentially third-to-market asset. The firm anticipates Vir to trade up Monday on the news and believes the company’s HDV program is underappreciated by investors and not adequately reflected in the stock at current levels.

2 · Reply

TDMF123 Dec. 8 at 8:33 PM

$VIR SoftBank going to def kill any strong upside momentum as they scale out. Looking forward to Phase 1 in Q1 where the catalyst will push the price regardless of SoftBank. If it wasn’t for them, we would easily be $8.00 right now

0 · Reply

triangkle Dec. 8 at 8:28 PM

$VIR Increased my position. The top is yet to come! Remember the beginning of this year, VIR did the same play and released great news Q1. Let's go!

0 · Reply

Quantumup Dec. 8 at 8:16 PM

Baird⬆️the PT on $MIRM to $88 from $80, reiterated at Outperform and said, Raising target price to $88 on acquisition. $GILD $VIR $ARWR $JNJ Baird added, The agreement to acquire Bluejay Therapeutics for $620M in cash/stock and up to $200M tiered sales milestones brings in a shot on goal at HDV in brelovitug. The drug has already demonstrated a 100% HDV RNA response in Ph2, and with a Ph3 readout expected 2H26, we think this can be an approvable drug and believe the high unmet need supports the expectation for peak sales to exceed half a billion dollars annually.

0 · Reply

triangkle Dec. 8 at 2:24 PM

$VIR strong premarket 🚀

0 · Reply

triangkle Dec. 5 at 11:07 PM

$VIR I'ma leave this here

1 · Reply

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

Nov 9, 2025, 6:07 PM EST - 4 weeks ago

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

Nov 7, 2025, 9:00 AM EST - 5 weeks ago

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Nov 5, 2025, 9:41 PM EST - 5 weeks ago

Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 5 weeks ago

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 8:00 AM EST - 5 weeks ago

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

Oct 22, 2025, 4:05 PM EDT - 7 weeks ago

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 9, 2025, 4:05 PM EDT - 2 months ago

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

Oct 7, 2025, 8:00 AM EDT - 2 months ago

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025

Sep 16, 2025, 1:15 PM EDT - 3 months ago

Vir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 25, 2025, 4:05 PM EDT - 3 months ago

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 7, 2025, 12:32 AM EDT - 4 months ago

Vir (VIR) Q2 Revenue Drops 61%

Aug 6, 2025, 11:01 PM EDT - 4 months ago

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 4 months ago

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 8:05 AM EDT - 4 months ago

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Jul 31, 2025, 8:05 AM EDT - 4 months ago

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Jul 24, 2025, 8:05 AM EDT - 5 months ago

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Jul 23, 2025, 12:10 PM EDT - 5 months ago

Vir Biotechnology: Hep B And Cancer Projects March On

Jul 22, 2025, 4:05 PM EDT - 5 months ago

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

Jun 11, 2025, 7:00 AM EDT - 6 months ago

20 stocks you should avoid — no matter how well the market does

CORT CPRX CRK CRNC DDD LUMN LYV

May 28, 2025, 4:05 PM EDT - 7 months ago

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 20, 2025, 4:05 PM EDT - 7 months ago

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

May 12, 2025, 4:05 PM EDT - 7 months ago

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 9, 2025, 6:00 AM EDT - 7 months ago

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 8, 2025, 3:37 PM EDT - 7 months ago

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

May 7, 2025, 11:21 PM EDT - 7 months ago

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 7 months ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 8 months ago

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Apr 24, 2025, 9:30 AM EDT - 8 months ago

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Mar 21, 2025, 7:10 AM EDT - 9 months ago

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Mar 13, 2025, 8:05 AM EDT - 9 months ago

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Feb 26, 2025, 11:22 PM EST - 10 months ago

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 10 months ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 4:05 PM EST - 10 months ago

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 4:05 PM EST - 10 months ago

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Jan 13, 2025, 6:10 PM EST - 11 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 10, 2025, 2:32 PM EST - 1 year ago

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

Jan 9, 2025, 9:00 AM EST - 1 year ago

Vir Biotechnology: A Rocket Off Phase 1 Data

Jan 8, 2025, 12:28 PM EST - 1 year ago

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why

Jan 8, 2025, 7:45 AM EST - 1 year ago

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Dec 18, 2024, 9:30 AM EST - 1 year ago

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 12:57 PM EST - 1 year ago

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

Dec 12, 2024, 4:05 PM EST - 1 year ago

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Nov 26, 2024, 9:30 AM EST - 1 year ago

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Nov 25, 2024, 9:30 AM EST - 1 year ago

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 18, 2024, 9:15 PM EST - 1 year ago

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Nov 18, 2024, 4:05 PM EST - 1 year ago

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Nov 15, 2024, 11:00 AM EST - 1 year ago

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

Nov 5, 2024, 11:29 AM EST - 1 year ago

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Oct 31, 2024, 11:12 PM EDT - 1 year ago

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript

Dunnieboy1 Dec. 10 at 8:06 PM

4 · Reply

VIR_Tical1 Dec. 9 at 9:18 PM

0 · Reply

VIR_Tical1 Dec. 9 at 9:15 PM

0 · Reply

Dunnieboy1 Dec. 9 at 5:16 PM

$VIR are we building up to a ‘santa rally’, December historically is a strong month for the markets, with the 5 days leading up to xmas & the two days prior to new year being particularly strong.

0 · Reply

VIR_Tical1 Dec. 9 at 2:10 AM

2 · Reply

TDMF123 Dec. 8 at 8:33 PM

0 · Reply

triangkle Dec. 8 at 8:28 PM

$VIR Increased my position. The top is yet to come! Remember the beginning of this year, VIR did the same play and released great news Q1. Let's go!

0 · Reply

Quantumup Dec. 8 at 8:16 PM

0 · Reply

triangkle Dec. 8 at 2:24 PM

$VIR strong premarket 🚀

0 · Reply

triangkle Dec. 5 at 11:07 PM

$VIR I'ma leave this here

1 · Reply

Dunnieboy1 Dec. 5 at 7:56 PM

$VIR could we have a recovery into the close, i think we could but i’m always optimistic & often wrong😂

1 · Reply

triangkle Dec. 5 at 7:42 PM

$VIR 🏃‍♂️ time

0 · Reply

Pharm_Hand Dec. 5 at 4:52 PM

$VIR So tired of the weakness here.

1 · Reply

TDMF123 Dec. 5 at 4:27 PM

$VIR I can’t say for sure if this is profit taking or SoftBank now selling again. I still can’t believe we still haven’t seen any analyst notes from Evercore

0 · Reply

triangkle Dec. 5 at 4:03 PM

$VIR morning selloff followed by a run

0 · Reply

TDMF123 Dec. 5 at 1:55 PM

$VIR let’s see if we can cross and hold $7.00 today.

1 · Reply

PCIntern Dec. 5 at 10:38 AM

$VIR up .51 premarket early AM FWIW

0 · Reply

PCIntern Dec. 4 at 10:16 PM

$VIR I’m reasonably pleased. 👍

1 · Reply

frontiere Dec. 4 at 8:25 PM

$JANX Janux ref=$16.49 $VIR Vir ref=$6.82 — NO pstn, was long VIR, full exit today to re-evaluate esp after the New Year — VIR maybe running on Janux fail with their PSMA x CD3 due to: 1) Dual masked such they don't need to spend time on CRS mitigation optimization 2) Q3W dosing from the start vs. JANX focusing more on "patient friendly" Q2W from starting QW maybe

1 · Reply

Dunnieboy1 Dec. 4 at 7:07 PM

$VIR who would of thought it Vir is showing a bit of resilience at last & we fought back from this week’s falls, think since TDMF has come on board our luck has changed👍

1 · Reply

SuperGreenToday Dec. 4 at 5:25 PM

$VIR Share Price: $6.49 Contract Selected: Jul 17, 2026 $5 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.03 – $2.48 Potential Upside: 50% ROI Time to Expiration: 224 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

TDMF123 Dec. 3 at 9:15 PM

$VIR She really did do a wonderful job. Especially on the Janx differentiation. Let’s hope Analysts do their part now . An upgrade is definitely well earned and deserved!

2 · Reply

Market Cap	930.75M
Revenue (ttm)	74.21M
Net Income (ttm)	-521.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-703.36%
Debt to Equity Ratio	0.00

Volume	1,212,000
Avg Vol	1,622,242
Day's Range	N/A - N/A
Shares Out	139.13M
Stochastic %K	77%
Beta	1.34
Analysts	Strong Sell
Price Target	$17.22